[go: up one dir, main page]

MX2022006004A - Proteinas de fusion inmunomoduladoras y usos de las mismas. - Google Patents

Proteinas de fusion inmunomoduladoras y usos de las mismas.

Info

Publication number
MX2022006004A
MX2022006004A MX2022006004A MX2022006004A MX2022006004A MX 2022006004 A MX2022006004 A MX 2022006004A MX 2022006004 A MX2022006004 A MX 2022006004A MX 2022006004 A MX2022006004 A MX 2022006004A MX 2022006004 A MX2022006004 A MX 2022006004A
Authority
MX
Mexico
Prior art keywords
fusion proteins
immunomodulatory fusion
cell
immunomodulatory
ligation
Prior art date
Application number
MX2022006004A
Other languages
English (en)
Inventor
Philip D Greenberg
Shannon K Oda
Thomas M Schmitt
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of MX2022006004A publication Critical patent/MX2022006004A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción se refiere a proteínas de fusión inmunomoduladoras que contienen un dominio de ligación extracelular y un dominio de señalización intracelular, en donde la ligación de un objetivo puede generar una señal moduladora en una célula hospedera, tal como una célula T. la presente descripción también se refiere a usos de células inmunitarias que expresan estas proteínas de fusión inmunomoduladoras parara tratar ciertas enfermedades, tales como cáncer o enfermedad infecciosa.
MX2022006004A 2015-03-05 2017-08-31 Proteinas de fusion inmunomoduladoras y usos de las mismas. MX2022006004A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562128979P 2015-03-05 2015-03-05

Publications (1)

Publication Number Publication Date
MX2022006004A true MX2022006004A (es) 2022-06-22

Family

ID=55587371

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2017011201A MX2017011201A (es) 2015-03-05 2016-03-04 Proteinas de fusion inmunomoduladoras y usos de las mismas.
MX2022006004A MX2022006004A (es) 2015-03-05 2017-08-31 Proteinas de fusion inmunomoduladoras y usos de las mismas.
MX2022006006A MX2022006006A (es) 2015-03-05 2017-08-31 Proteinas de fusion inmunomoduladoras y usos de las mismas.
MX2022006002A MX2022006002A (es) 2015-03-05 2017-08-31 Proteinas de fusion inmunomoduladoras y usos de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017011201A MX2017011201A (es) 2015-03-05 2016-03-04 Proteinas de fusion inmunomoduladoras y usos de las mismas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022006006A MX2022006006A (es) 2015-03-05 2017-08-31 Proteinas de fusion inmunomoduladoras y usos de las mismas.
MX2022006002A MX2022006002A (es) 2015-03-05 2017-08-31 Proteinas de fusion inmunomoduladoras y usos de las mismas.

Country Status (17)

Country Link
US (3) US20180044404A1 (es)
EP (2) EP3265481B1 (es)
JP (3) JP6917896B2 (es)
KR (1) KR20170120701A (es)
CN (1) CN107531805A (es)
AU (3) AU2016226022B2 (es)
BR (1) BR112017018919A8 (es)
CA (2) CA3177938A1 (es)
ES (1) ES2979088T3 (es)
HK (1) HK1246317A1 (es)
IL (1) IL254165B (es)
MX (4) MX2017011201A (es)
MY (2) MY189195A (es)
RU (1) RU2755227C2 (es)
SA (1) SA517382216B1 (es)
SG (2) SG11201707182WA (es)
WO (1) WO2016141357A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3143134B1 (en) 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
EP4427809A3 (en) 2014-10-31 2024-12-04 The Trustees of The University of Pennsylvania Altering gene expression in car-t cells and uses thereof
CN107531805A (zh) 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
KR20180029201A (ko) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
EP3394092A1 (en) 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
EP4286522A3 (en) 2016-03-23 2024-02-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
CN109475628A (zh) 2016-05-18 2019-03-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
WO2018009972A1 (en) * 2016-07-14 2018-01-18 Peter Maccallum Cancer Institute Chimeric antigen receptor modified t cells
AU2017297506A1 (en) 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
US20200095547A1 (en) * 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
AU2017379900B2 (en) 2016-12-22 2024-12-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3038150A1 (en) * 2016-12-22 2018-06-28 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
EP3595706A1 (en) * 2017-03-17 2020-01-22 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
EP3601537A4 (en) 2017-03-27 2021-01-13 National University of Singapore STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
SG11201908492PA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
AU2018312222B2 (en) 2017-08-02 2024-11-21 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
JP2021500855A (ja) * 2017-09-07 2021-01-14 キュー バイオファーマ， インコーポレイテッド 抗原提示ポリペプチドおよびその使用方法
WO2019055862A1 (en) 2017-09-14 2019-03-21 Fred Hutchinson Cancer Research Center HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same
CN118256563A (zh) * 2017-11-10 2024-06-28 北京卡替医疗技术有限公司 一种扩增免疫细胞的方法
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
KR20200138741A (ko) 2018-04-02 2020-12-10 내셔널 유니버시티 오브 싱가포르 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
KR20210025054A (ko) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 이형이량체 단백질 및 이의 용도
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102261407B1 (ko) * 2018-10-10 2021-06-08 한국화학연구원 Hvem을 표적으로 하는 키메라 항원 수용체
US20210393692A1 (en) * 2018-11-13 2021-12-23 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
TWI856047B (zh) 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
US12448430B2 (en) 2019-03-11 2025-10-21 Fred Hutchinson Cancer Center High avidity WT1 T cell receptors and uses thereof
CN113710697A (zh) * 2019-03-15 2021-11-26 美国政府(由卫生和人类服务部的部长所代表) 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途
WO2020188105A1 (en) * 2019-03-21 2020-09-24 Onk Therapeutics Limited Modified immune effector cells with increased resistance to cell death
SG11202111130SA (en) 2019-04-30 2021-11-29 Senti Biosciences Inc Chimeric receptors and methods of use thereof
EP3999079A4 (en) * 2019-07-19 2024-04-03 Memorial Sloan Kettering Cancer Center Fusion polypeptide for immunotherapy
KR20220106803A (ko) * 2019-11-27 2022-07-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nk 세포에 대한 대규모 조합형 car 형질도입 및 crispr 유전자 편집
WO2021104511A1 (zh) * 2019-11-29 2021-06-03 苏州诺沃泰医药科技有限公司 Cart细胞在制备治疗癌症的药物中的应用
CA3161488A1 (en) * 2019-12-11 2021-06-17 Daniel Getts Therapeutic cell compositions and methods for manufacture and uses thereof
EP4092053A4 (en) * 2020-01-19 2024-01-17 Chineo Medical Technology Co., Ltd. ENHANCED RECEPTOR TO IMPROVE IMMUNE CELL FUNCTION
US20230133554A1 (en) * 2020-04-09 2023-05-04 Autolus Limited Molecule
GB202101491D0 (en) * 2021-02-03 2021-03-17 Autolus Ltd Molecule
US20230113183A1 (en) * 2020-04-09 2023-04-13 Autolus Limited Cell
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
BR112022023371A2 (pt) * 2020-05-22 2022-12-20 Chongqing Prec Biotech Co Ltd Proteína de fusão para reversão do microambiente tumoral, vetor de expressão, célula imune, receptor de antígeno quimérico resistente à imunossupressão tumoral, sequência de ácido nucleico, método para preparar uma célula imune, composição farmacêutica, e, uso da composição farmacêutica
IL299886A (en) 2020-07-17 2023-03-01 Instil Bio Uk Ltd Receptors that provide targeted costimulation for host cell therapy
US20230295564A1 (en) * 2020-07-23 2023-09-21 Emory University Galectin-9 Specific Binding Agents for Use in Treating Cancer
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
CA3211402A1 (en) * 2021-03-10 2022-09-15 Moshe ELKABETS Reporter cells expressing chimeric polypeptides for use in determining presence and or activity of immune checkpoint molecules
WO2022246041A2 (en) * 2021-05-20 2022-11-24 Achelois Biopharma, Inc. Compositions and methods for multivalent surface display on enveloped particles
WO2022246053A2 (en) * 2021-05-20 2022-11-24 Achelois Biopharma, Inc. Immune checkpoint multivalent particles compositions and methods of use
EP4355340A4 (en) 2021-06-16 2025-05-21 Instil Bio, Inc. RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
WO2023288278A1 (en) 2021-07-16 2023-01-19 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
CN113621077B (zh) * 2021-09-02 2023-01-31 山东大学 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
EP4476246A2 (en) * 2022-02-07 2024-12-18 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding
IL321438A (en) * 2022-12-15 2025-08-01 Kalivir Immunotherapeutics Inc Compositions of CD47/SIRP-ALPHA immune checkpoint inhibitors and their uses
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
EP4599843A1 (en) 2024-02-09 2025-08-13 Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau Car and modified cd200r combination
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1999A (en) 1841-03-12 Improvement in seed-planters
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
ES2229236T3 (es) 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
WO1996013584A1 (en) 1994-11-01 1996-05-09 Targeted Genetics Corporation Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
JP5563194B2 (ja) 2004-06-29 2014-07-30 イムノコア リミテッド 改変ｔ細胞レセプターを発現する細胞
AU2006204459B2 (en) 2005-01-05 2012-11-01 F-Star Therapeutics Limited Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
JP2010539915A (ja) 2007-09-24 2010-12-24 ユニバーシティ・オブ・チューリッヒ 設計されたアルマジロリピートタンパク質
WO2012012695A2 (en) * 2010-07-23 2012-01-26 Fred Hutchinson Cancer Research Center A method for the treatment of obesity
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR101976882B1 (ko) * 2011-03-23 2019-05-09 프레드 헛친슨 켄서 리서치 센터 세포 면역요법용 방법 및 조성물
NZ723731A (en) 2011-04-08 2020-05-29 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
PE20141520A1 (es) 2011-07-29 2014-11-17 Univ Pennsylvania Receptores coestimuladores de cambio
KR101471647B1 (ko) 2011-10-26 2014-12-11 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
JP6850528B2 (ja) * 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
CA2896989A1 (en) 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
EP2943565B1 (en) * 2013-01-14 2018-03-28 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
CN103965361B (zh) 2013-02-06 2018-10-30 上海细胞治疗工程技术研究中心集团有限公司 一种t细胞信号的嵌合分子转换器及其用途
WO2014172584A1 (en) 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
CN107109420A (zh) 2014-07-21 2017-08-29 诺华股份有限公司 使用cll－1嵌合抗原受体的癌症治疗
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
BR112017001242A2 (pt) 2014-07-21 2017-12-05 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico a cd33
JP6712261B2 (ja) * 2014-08-04 2020-06-24 フレッド ハッチンソン キャンサー リサーチ センター Ｗｔ−１に特異的なｔ細胞免疫治療
WO2016024021A1 (en) * 2014-08-15 2016-02-18 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins
HRP20240357T1 (hr) 2014-12-24 2024-06-07 Autolus Limited Stanica
JP6734283B2 (ja) * 2015-01-21 2020-08-05 フレッド ハッチンソン キャンサー リサーチ センター 遺伝子治療用ポイントオブケア及び／又はポータブルプラットフォーム
CN107531805A (zh) 2015-03-05 2018-01-02 弗雷德哈钦森癌症研究中心 免疫调节融合蛋白及其用途
PT3310805T (pt) 2015-06-19 2021-05-19 Kobold Sebastian Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
WO2017088012A1 (en) 2015-11-27 2017-06-01 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
EP3394092A1 (en) * 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
US10188749B2 (en) * 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
JP7198670B2 (ja) * 2016-04-20 2023-01-04 フレッド ハッチンソン キャンサー センター 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用
EP3595706A1 (en) * 2017-03-17 2020-01-22 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
WO2019061012A1 (zh) 2017-09-26 2019-04-04 南京凯地生物科技有限公司 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用
CN110330567B (zh) 2019-07-02 2020-11-06 南京凯地生物科技有限公司 双特异性嵌合抗原受体t细胞，其制备方法和应用

Also Published As

Publication number Publication date
JP2018508219A (ja) 2018-03-29
HK1246317A1 (zh) 2018-09-07
JP2020114264A (ja) 2020-07-30
CA2978186A1 (en) 2016-09-09
EP3265481B1 (en) 2024-05-01
EP4406604A3 (en) 2024-10-23
IL254165B (en) 2021-08-31
SG10201908203SA (en) 2019-10-30
BR112017018919A2 (pt) 2018-04-17
US20210403532A1 (en) 2021-12-30
AU2020244495B2 (en) 2022-12-01
RU2017133637A (ru) 2019-04-08
BR112017018919A8 (pt) 2023-04-11
US20250109180A1 (en) 2025-04-03
CA3177938A1 (en) 2016-09-09
MX2017011201A (es) 2018-01-30
SG11201707182WA (en) 2017-10-30
CN107531805A (zh) 2018-01-02
JP2021184771A (ja) 2021-12-09
MX2022006006A (es) 2022-06-22
RU2755227C2 (ru) 2021-09-14
US20180044404A1 (en) 2018-02-15
AU2016226022A1 (en) 2017-09-14
KR20170120701A (ko) 2017-10-31
AU2020244495A1 (en) 2020-10-29
AU2022271411A1 (en) 2022-12-22
EP3265481A1 (en) 2018-01-10
MY196588A (en) 2023-04-19
ES2979088T3 (es) 2024-09-24
IL254165A0 (en) 2017-10-31
US12012443B2 (en) 2024-06-18
WO2016141357A1 (en) 2016-09-09
SA517382216B1 (ar) 2022-11-30
MY189195A (en) 2022-01-31
JP6917896B2 (ja) 2021-08-18
JP7441201B2 (ja) 2024-02-29
AU2016226022B2 (en) 2020-07-09
MX2022006002A (es) 2022-06-17
JP7026161B2 (ja) 2022-02-25
RU2017133637A3 (es) 2019-08-08
EP4406604A2 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
MX2022006004A (es) Proteinas de fusion inmunomoduladoras y usos de las mismas.
MX2024000006A (es) Proteinas de fusion inmunomoduladoras y sus usos.
CL2024003234A1 (es) Polipéptidos modificados y usos de los mismos.
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
BR112018012707A2 (pt) inibidores da interação de menin-mll
WO2014116846A3 (en) Methods and compositions for modulating an immune response
MX2019008359A (es) Cadena j modificada.
MX382518B (es) Antigenos de citomegalovirus y su uso.
MX391279B (es) Anticuerpos biespecíficos contra cd3 y cd20.
CL2018000432A1 (es) Vacunas terapéuticas contra el hpv18
CR20150465A (es) Virus de la enfermedad de newcastle y usos de los mismos
TWD170353S (zh) 項鍊
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
AU362835S (en) Rack system
TW201613980A (en) Anti-tissue factor monoclonal antibody
MX2023006415A (es) Anticuerpos, usos y metodos.
AU357763S (en) Vessel
MY191539A (en) Streptococcal vaccine
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
MX378857B (es) Celulas huespedes modificadas y usos de las mismas.
UY34695A (es) Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
MX2021009154A (es) Selectividad eficaz de proteinas recombinantes.